NCT00273936View on ClinicalTrials.gov

Trial of AVN-944 in Patients With Advanced Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

January 31, 2006

Conditions
Acute LeukemiaChronic LeukemiaMultiple MyelomaHodgkin's LymphomaNon-Hodgkin's LymphomaWaldenstrom's Macroglobulinemia
Interventions
DRUG

AVN-944 capsules for oral administration

Trial Locations (5)

20037

George Washington University, Washington D.C.

43210

Ohio State University, James Cancer Hospital Comprehensive Cancer Center, Columbus

85715

Arizona Clinical Research Center, Tucson

94305

Stanford Cancer Center, Stanford

097239

Oregon Health and Science University, Portland

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT00273936 - Trial of AVN-944 in Patients With Advanced Hematologic Malignancies | Biotech Hunter | Biotech Hunter